Equibles does not estimate personal net worth.
Get an email with a short summary when Travere Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get TVTX alertsBill Rote has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Travere Therapeutics, Inc. on May 4, 2026. Travere Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Travere Therapeutics, Inc. includes Bradley Campbell (CEO and Board Member), Bradley L. Campbell (CEO and Board Member), Christopher Cline (CFO) and 7 others.
“We've got breakthrough therapy designation for PEG-T, so that allows us to have a lot of interaction with the FDA. And through that process, we reached alignment on the endpoint for that Harmony study.”
“This was a recent development, as you've heard on the call. We learned about the agency's preference for this subgroup early in March.”
Source not stated
Biotechnology · Healthcare
